Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on December 21, 2018, reporting events occurring on December 20 and 21, 2018. The filing focuses on clinical trial results for the Company's ADHD treatment candidate, SPN-812, and upcoming investor relations activities.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a current report regarding specific corporate events rather than a periodic financial report.
Material Changes and Clinical Developments
- Phase III Trial Success: The Company announced positive topline results from Phase III study P302 for SPN-812 in patients aged 12-17 with ADHD.
- Primary Endpoint Met: The study demonstrated statistically significant improvement in ADHD symptoms from baseline to the end of the study using the ADHD Rating Scale-5.
- Dosing and Safety: Daily doses of 200 mg and 400 mg were tested and found to be well tolerated.
- Upcoming Data: Topline data from the second Phase III trial (P304) in the same patient population are expected by the end of the first quarter of 2019.
Guidance, Outlook, and Management Commentary
- Regulatory Timeline: The Company expects to submit a New Drug Application (NDA) for SPN-812 in the second half of 2019.
- Commercial Launch: Pending FDA approval, the Company plans to launch SPN-812 in the second half of 2020.
- Investor Relations: Management is scheduled to present an overview and host investor meetings at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019.
Investor Verification Checklist
- Verify the statistical significance and clinical relevance of the ADHD Rating Scale-5 results in study P302.
- Monitor the release of topline data for study P304 expected in Q1 2019.
- Confirm the submission of the New Drug Application in H2 2019 and subsequent FDA review status.
- Review the full press release (Exhibit 99.1) for detailed safety data and adverse event profiles.